TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16981917

Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD (n=52)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single-chamber ICD (n=48)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD (n=52) with frequent ventricular pacing (≥35%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD (n=52) with low ventricular pacing (<35%)
Number of subjects: 100
Study: 15018377

Group type: EXPERIMENTAL
Intervention: Before and After diet advertisement
Number of subjects: 59

Group type: COMPARATOR
Intervention: Before Picture Only
Number of subjects: 59

Group type: COMPARATOR
Intervention: After Picture Only
Number of subjects: 59
Study: 10835457

Group type: EXPERIMENTAL
Intervention: Electromyography-triggered neuromuscular electrical stimulation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no external assistance for wrist and finger extension)
Number of subjects: 11
Study: 9357880

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 30
Study: 8256088

Group type: EXPERIMENTAL
Intervention: Ivermectin (multiple doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ivermectin (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3517694

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 31251888

Group type: EXPERIMENTAL
Intervention: H2 water
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 159
Study: 30013436

Group type: EXPERIMENTAL
Intervention: Palonosetron plus dexamethasone (group PD)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Palonosetron alone (group P)
Number of subjects: 202
Study: 27015909

Group type: EXPERIMENTAL
Intervention: Sustained-release dexamfetamine (60 mg/day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sustained-release dexamfetamine
Number of subjects: 73
Study: 24864199

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR; n = 18)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Calorie restriction with aerobic exercise (CR + Ex; n = 15)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (CR)
Number of subjects: 33
Study: 22325170

Group type: EXPERIMENTAL
Intervention: Adalimumab 160/80 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adalimumab 80/40 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adalimumab (maintenance 40 mg every other week)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (maintenance)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 90

Group type: COMPARATOR
Intervention: Adalimumab and Placebo
Number of subjects: 90
Study: 20396721

Group type: EXPERIMENTAL
Intervention: artrofoon
Number of subjects: 0
Study: 17240440

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey formula
Number of subjects: 2252

Group type: COMPARATOR
Intervention: Cow's milk formula
Number of subjects: 2252
Study: 15020173

Group type: EXPERIMENTAL
Intervention: Tailored, motivational outreach
Number of subjects: 254

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 254
Study: 12059886

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil-ropivacaine infusion with epinephrine (n=32)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Epidural sufentanil-ropivacaine infusion without epinephrine (n=29)
Number of subjects: 61
Study: 9822001

Group type: EXPERIMENTAL
Intervention: Forced-air warming (normothermia group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care (hypothermia group)
Number of subjects: 60
Study: 8126039

Group type: EXPERIMENTAL
Intervention: Hypotensive epidural anesthesia, external pneumatic-compression boots, and aspirin (Group I)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Hypotensive epidural anesthesia and aspirin (Group II)
Number of subjects: 231
Study: 2531270

Group type: EXPERIMENTAL
Intervention: SPG plus tegafur‐‐F method or 5‐FU combined with MMC‐‐MF method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPG administered intramuscularly 40mg/week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (chemotherapy only)
Number of subjects: 0
Study: 779750

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (Calciparine)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30549146

Group type: EXPERIMENTAL
Intervention: Collaborative Care Skills Workshops
Number of subjects: 63

Group type: COMPARATOR
Intervention: Psycho-educational Workshops
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 63
Study: 28503541

Group type: EXPERIMENTAL
Intervention: Core stabilization exercise (3 sessions per week for 12 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 25894430

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 22739993

Group type: EXPERIMENTAL
Intervention: Ultrasound guided steroid injection
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Palpation guided steroid injection
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both active treatment groups (ultrasound guided and unguided)
Number of subjects: 65
Study: 21708186

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle pattern (HLP) score of 4
Number of subjects: 7000
Study: 17457551

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard access surgery
Number of subjects: 0
Study: 16332655

Group type: EXPERIMENTAL
Intervention: High dietary calcium intake (1000-1400 mg/d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low dietary calcium intake (<800 mg/d, control)
Number of subjects: 19
Study: 12547447

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9873847

Group type: EXPERIMENTAL
Intervention: plasma‐derived concentrates
Number of subjects: 65

Group type: COMPARATOR
Intervention: fresh frozen plasma (FFP)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: low-dose concentrate at 25 IU kg‐1 twice weekly
Number of subjects: 65
Study: 7625802

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 190

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 190
Study: 2664088

Group type: EXPERIMENTAL
Intervention: Intravenous methylphenidate (MTP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 850062

Group type: EXPERIMENTAL
Intervention: Preparation (experimental group)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Continued inpatient care (control group)
Number of subjects: 572
Study: 29975969

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided surgery
Number of subjects: 47

Group type: COMPARATOR
Intervention: Wire localization surgery
Number of subjects: 47
Study: 27628210

Group type: EXPERIMENTAL
Intervention: Injury prevention intervention (physician wearing a customized scrub top)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control shift (no customized scrub top)
Number of subjects: 14
Study: 26446582

Group type: EXPERIMENTAL
Intervention: Thyroid hormone withdrawal (THW)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Recombinant human thyrotropin (rhTSH)
Number of subjects: 28
Study: 23427483

Group type: EXPERIMENTAL
Intervention: Patellar replacement
Number of subjects: 63

Group type: COMPARATOR
Intervention: Non patellar replacement
Number of subjects: 63
Study: 22045142

Group type: EXPERIMENTAL
Intervention: Noninvasive electromagnetic device
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional blind technique
Number of subjects: 49
Study: 19225395

Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adaptive pressure ventilation (APV)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All modes (ASV, PSV, APV)
Number of subjects: 14
Study: 17042908

Group type: EXPERIMENTAL
Intervention: Tulobuterol patch, 2 mg once daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 mg twice daily
Number of subjects: 54
Study: 15117110

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study: 12230092

Group type: EXPERIMENTAL
Intervention: ECG-gated myocardial perfusion SPECT after exercise
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ECG-gated myocardial perfusion SPECT at rest and peak stress
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ECG-gated myocardial perfusion SPECT
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison of LVESV changes between Groups N and I
Number of subjects: 19
Study: 9477281

Group type: EXPERIMENTAL
Intervention: CO2
Number of subjects: 105

Group type: COMPARATOR
Intervention: Air
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 50/50 mixture
Number of subjects: 105
Study: 7715220

Group type: EXPERIMENTAL
Intervention: Bicaval technique (group A)
Number of subjects: 75
Study: 2621401

Group type: EXPERIMENTAL
Intervention: Dynamic traction
Number of subjects: 51

Group type: COMPARATOR
Intervention: Immobilisation (Control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dynamic mobilisation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Fixed splintage (Control)
Number of subjects: 51
Study: 839326

Group type: EXPERIMENTAL
Intervention: Formula 1 (F1) = 1.5gm/dl protein, 60 parts bovine whey proteins: 40 parts bovine caseins
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Formula 2 (F2) = 3.0 gm/dl, 60:40
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Formula 3 (F3) = 1.5 gm/dl, 18:82
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Formula 4 (F4) = 3.0 gm/dl, 18:82
Number of subjects: 5

Group type: COMPARATOR
Intervention: Pooled human milk (BM)
Number of subjects: 5
Study: 30949628

Group type: EXPERIMENTAL
Intervention: Chlorhexidine acid (CHX acid)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Proanthocyanidin acid (PA acid)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional phosphoric acid (CP acid)
Number of subjects: 126
Study: 26984753

Group type: EXPERIMENTAL
Intervention: Project K youth development program
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study: 25771760

Group type: EXPERIMENTAL
Intervention: Mega heated and humidified breathing circuit (group M)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fisher & Paykel HHBC (group F)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional breathing circuit (group C)
Number of subjects: 102
Study: 23682096

Group type: EXPERIMENTAL
Intervention: LB03002 (SR-hGH) administered once weekly at a dose of 0.5 mg/kg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Daily rhGH administered for 6 consecutive days at a total of 0.21 mg/kg per week
Number of subjects: 63
Study: 21235334

Group type: COMPARATOR
Intervention: Etoricoxib 120 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Celecoxib 200 mg (and another 200 mg 12 hours after the first dose)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 56
Study: 19710642

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17875873

Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate PDT
Number of subjects: 97

Group type: COMPARATOR
Intervention: Excision surgery
Number of subjects: 97
Study: 15033894

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg (Group RO)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg (Group DE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Group PL)
Number of subjects: 120
Study: 11392449

Group type: EXPERIMENTAL
Intervention: Oral docetaxel in combination with cyclosporin A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral paclitaxel in combination with cyclosporin A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral route for both taxanes
Number of subjects: 0
Study: 9597203

Group type: EXPERIMENTAL
Intervention: Adductor pollicis (AP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Orbicularis oculi (OO)
Number of subjects: 40
Study: 7946934

Group type: EXPERIMENTAL
Intervention: CNS 1102, 30 micrograms kg‐1 and above
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CNS 1102, 45 micrograms kg‐1 and above
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CNS 1102, maximum tolerated dose 30 micrograms kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CNS 1102, administered as a 15 min intravenous infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CNS 1102
Number of subjects: 0
Study: 17171905

Group type: EXPERIMENTAL
Intervention: Sufentanil, 20 microg/kg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fentanyl, 100 microg/kg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isoflurane, 1.6%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Halothane, 0.9%
Number of subjects: 48
Study: 30710315

Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 210

Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 210
Study: 30158356

Group type: EXPERIMENTAL
Intervention: Edoxaban Tosilate Hydrate
Number of subjects: 0
Study: 26576860

Group type: EXPERIMENTAL
Intervention: LUCAS-CPR
Number of subjects: 12

Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 12
Study: 25012446

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50mg/d
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study: 22729716

Group type: EXPERIMENTAL
Intervention: EC + GA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GA + EA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EC + GA + EA
Number of subjects: 60

Group type: COMPARATOR
Intervention: GA
Number of subjects: 60
Study: 20418304

Group type: COMPARATOR
Intervention: Constant infusion rate group (normal saline 0.9% at an infusion rate 10 to 12 mL . kg(‐1) . h(‐1))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Central venous pressure target (CVPT) group (normal saline 0.9% titrated to maintain a specific CVP of 5 mm Hg and 15 mm Hg during specific intervals)
Number of subjects: 40
Study: 18069215

Group type: EXPERIMENTAL
Intervention: Oral oestrogen therapy (2 mg daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Transdermal oestrogen therapy (0.05 mg daily)
Number of subjects: 45
Study: 15723234

Group type: EXPERIMENTAL
Intervention: TachoSil (carrier‐bound fibrin sealant)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Argon beamer (argon beam coagulator)
Number of subjects: 121
Study: 11857418

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 163126

Group type: EXPERIMENTAL
Intervention: Pooling data with the PLCO trial
Number of subjects: 163126
Study: 9713640

Group type: EXPERIMENTAL
Intervention: salmeterol 50 micrograms twice daily
Number of subjects: 225

Group type: COMPARATOR
Intervention: comparator agents (placebo or salbutamol)
Number of subjects: 225
Study: 7869204

Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation (PLV)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Surfactant (Exosurf) plus CMV
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Surfactant plus PLV
Number of subjects: 22
Study: 2237557

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 274262

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat) applied 5 or 6 times over 3 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31523888

Group type: EXPERIMENTAL
Intervention: Web-based Intelligent Tutoring System for the Text Structure Strategy (ITSS)
Number of subjects: 260
Study: 30653578

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27822702

Group type: EXPERIMENTAL
Intervention: Daily WeChat services on cell phone for adherence to corticosteroid nasal spray treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No WeChat services (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray 128 µg bid (given to all subjects).
Number of subjects: 0
Study: 27067343

Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil (GEn) 600 mg
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil (GEn) 1200 mg
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Gabapentin Enacarbil (GEn) 600 mg and 1200 mg
Number of subjects: 671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study: 25471080

Group type: EXPERIMENTAL
Intervention: Subcutaneous specific immunotherapy (SIT) with PURETHAL® Mites for 8 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Medication to treat symptoms only (Control group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups (SIT and Control)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: SIT group
Number of subjects: 43
Study: 22304836

Group type: EXPERIMENTAL
Intervention: Daily grapefruit (1/2 fresh Rio-Red grapefruit with each meal, 3× daily for 6 weeks)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 74
Study: 19513811

Group type: EXPERIMENTAL
Intervention: Single oral doses of tetrahydrobiopterin (BH(4))
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Statistical process control (SPC)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH(4))
Number of subjects: 17
Study: 17627490

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 421

Group type: COMPARATOR
Intervention: Caregiver support
Number of subjects: 421
Study: 16336497

Group type: EXPERIMENTAL
Intervention: 6 mg tegaserod
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16824992

Group type: EXPERIMENTAL
Intervention: Ultrasonic strain rate imaging before PCI
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ultrasonic strain rate imaging 3 days after PCI
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ultrasonic strain rate imaging 5 months after PCI
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging after 5 months
Number of subjects: 41
Study: 11039962

Group type: EXPERIMENTAL
Intervention: Lipid lowering drugs (duration: five to seven years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid lowering drugs
Number of subjects: 0
Study: 8667325

Group type: EXPERIMENTAL
Intervention: J95 health data collection system
Number of subjects: 0
Study: 1825744

Group type: EXPERIMENTAL
Intervention: 0.1% thymoxamine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 6863582

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 25 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 75 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 100 mg
Number of subjects: 7
Study: 31776371

Group type: EXPERIMENTAL
Intervention: 600 IU/d of vitamin D3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4,000 IU/d of vitamin D3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10,000 IU/d of vitamin D3
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 30613058

Group type: EXPERIMENTAL
Intervention: Communication Empowerment Program based on Situated Learning Theory (8 sessions, twice a week, 2 hours each)
Number of subjects: 61
Study: 26467666

Group type: EXPERIMENTAL
Intervention: HPV16/18 vaccine (Cervarix)
Number of subjects: 4186
Study: 25178568

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (<40 g/d)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Low-fat diet (<30% of daily energy intake from total fat)
Number of subjects: 148
Study: 23043943

Group type: EXPERIMENTAL
Intervention: Flutamide (administered prenatally between Days 80 and 88 of gestation and neonatally between Days 2 and 10 postnatally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flutamide (administered prenatally and neonatally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flutamide (neonatal exposure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flutamide (prenatal and neonatal exposure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (nontreated pigs)
Number of subjects: 0
Study: 20389163

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17894911

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study: 15944796

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/mitomycin adjuvant chemotherapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 160
Study: 12858127

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol
Number of subjects: 0
Study: 10232563

Group type: EXPERIMENTAL
Intervention: Neoral (NEO)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Sandimmune (SIM)
Number of subjects: 188
Study: 8724018

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 15

Group type: COMPARATOR
Intervention: Seated position
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 15
Study: 1858699

Group type: EXPERIMENTAL
Intervention: High linoleic acid diet (11.5% of energy)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low linoleic acid diet (4.5% of energy)
Number of subjects: 7
Study: 31600804

Group type: EXPERIMENTAL
Intervention: Epidural
Number of subjects: 65

Group type: COMPARATOR
Intervention: PCA
Number of subjects: 65